The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial.

Autor:	de Almeida CMO; School of Health Sciences, State University of Amazonas, Manaus, Brazil., Brito MMC; Division of Neurology, Department of Neuroscience and Sciences of Behavior, Faculty of Medicine, University of São Paulo, Ribeirão Preto, Brazil., Bosaipo NB; Division of Neurology, Department of Neuroscience and Sciences of Behavior, Faculty of Medicine, University of São Paulo, Ribeirão Preto, Brazil., Pimentel AV; Division of Neurology, Department of Neuroscience and Sciences of Behavior, Faculty of Medicine, University of São Paulo, Ribeirão Preto, Brazil., Sobreira-Neto MA; Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Brazil., Tumas V; Division of Neurology, Department of Neuroscience and Sciences of Behavior, Faculty of Medicine, University of São Paulo, Ribeirão Preto, Brazil., Zuardi AW; Division of Neurology, Department of Neuroscience and Sciences of Behavior, Faculty of Medicine, University of São Paulo, Ribeirão Preto, Brazil.; National Institute of Science and Technology in Translational Medicine, CNPq/FAPESP/CAPES, Ribeirão Preto, Brazil., Crippa JAS; Division of Neurology, Department of Neuroscience and Sciences of Behavior, Faculty of Medicine, University of São Paulo, Ribeirão Preto, Brazil.; National Institute of Science and Technology in Translational Medicine, CNPq/FAPESP/CAPES, Ribeirão Preto, Brazil., Hallak JEC; Division of Neurology, Department of Neuroscience and Sciences of Behavior, Faculty of Medicine, University of São Paulo, Ribeirão Preto, Brazil.; National Institute of Science and Technology in Translational Medicine, CNPq/FAPESP/CAPES, Ribeirão Preto, Brazil., Eckeli AL; Division of Neurology, Department of Neuroscience and Sciences of Behavior, Faculty of Medicine, University of São Paulo, Ribeirão Preto, Brazil.
Jazyk:	angličtina
Zdroj:	Cannabis and cannabinoid research [Cannabis Cannabinoid Res] 2023 Apr; Vol. 8 (2), pp. 374-378. Date of Electronic Publication: 2022 Jun 24.
DOI:	10.1089/can.2021.0158
Abstrakt:	Background: Cannabidiol (CBD) is one of the main nonpsychoactive components of Cannabis sativa and may represent an alternative treatment for Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) in patients with Parkinson's disease (PD) and REM (Rapid Eye Movement) sleep behavior disorder (RBD). Objective: Our purpose was a post hoc exploratory analysis to evaluate the CBD's efficacy to improve the severity of RLS/WED symptoms in patients with PD and RBD. Methods: A post hoc exploratory analysis of a phase II/III, a parallel, double-blind, placebo-controlled clinical trial was conducted in 18 patients with RLS/WED and PD plus RBD associated. Six patients were randomized to the CBD group in doses of 75-300 mg, and twelve received placebo capsules. They were followed up for 14 weeks. The primary outcome was the severity of RLS/WED by Restless Legs Syndrome Rating Scale of the International Restless Legs Syndrome Study Group (IRLSSG). Results: CBD showed no difference in relationship to placebo for primary and secondary outcomes. Conclusion: CBD showed no reduction in the severity of RLS/WED manifestation in patients with PD and RBD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu